Anzeige
❌
Mehr »
Montag, 16.11.2026 - Börsentäglich über 12.000 News
Pelican AI: +34,75% in Frankfurt! Ist das erst der Anfang einer großen Kursrallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
NL

WKN: A41ESB | ISIN: CNE1000070H8 | Ticker: 0DX
Frankfurt
12.11.26 | 08:55
4,180 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
NANJING LEADS BIOLABS CO LTD Chart 1 Jahr
5-Tage-Chart
NANJING LEADS BIOLABS CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
4,0204,10015.11.
4,0204,10013.11.

Aktuelle News zur NANJING LEADS BIOLABS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.10.LEADS BIOLABS CO., LTD.: Leads Biolabs Doses First Patient with Systemic Lupus Erythematosus in Phase I Part B Trial of LBL-047, a First-in-Class BDCA2/TACI Bifunctional Fusion Protein2
NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln
30.10.LEADS BIOLABS-B Completes First Dosing of Systemic Lupus Erythematosus Patient in Part B of Phase I Study for LBL-0473
30.10.LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PART B OF LBL-047 PHASE I STUDY COMPLETES FIRST DOSING OF A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS; ...1
26.10.LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PRESENTATION OF UPDATED CLINICAL AND TRANSLATIONAL DATA OF LBL-024 FOR EXTRAPULMONARY NEUROENDOCRINE CARCINOMA, ...-
26.10.LEADS BIOLABS-B Preparing Phase III Clinical Trial for LBL-0344
25.10.LEADS BIOLABS CO., LTD.: Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform5
20.10.LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Stage in Phase II First-Line Gastric Cancer Study1
20.10.LEADS BIOLABS-B Phase II Study of Leadsin for First-line Gastric Cancer Treatment Enters Expansion Stage1
20.10.LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PHASE II STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) AS FIRST-LINE TREATMENT FOR ...-
19.10.LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig and LBL-034 Featured in Six Abstracts at 2026 ESMO Congress1
19.10.LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT ABSTRACTS OF SIX STUDIES PUBLISHED AT 2026 ESMO1
16.10.LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer1
16.10.LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN PHASE IB/II CLINICAL TRIAL OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ...3
12.10.LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer1
12.10.LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA ...1
28.09.LEADS BIOLABS CO., LTD.: Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition5
28.09.LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED ORPHAN DRUG DESIGNATION IN JAPAN1
23.09.LEADS BIOLABS-B (09887): 2026 INTERIM REPORT1
21.09.LEADS BIOLABS CO., LTD.: Leads Biolabs' Pivotal Phase IIb Study of Opamtistomig (LBL-024) in Advanced EP-NEC Selected as ESMO 2026 Late-Breaking Abstract; Three Studies Selected for Proffered Paper Presentations6
21.09.LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PIVOTAL REGISTRATIONAL PHASE IIB STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) MONOTHERAPY ...1
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1